OmniAb Q4 2023 Earnings Report $3.21 +0.03 (+0.94%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast OmniAb EPS ResultsActual EPS-$0.14Consensus EPS -$0.17Beat/MissBeat by +$0.03One Year Ago EPSN/AOmniAb Revenue ResultsActual Revenue$4.82 millionExpected Revenue$6.94 millionBeat/MissMissed by -$2.12 millionYoY Revenue GrowthN/AOmniAb Announcement DetailsQuarterQ4 2023Date3/20/2024TimeN/AConference Call ResourcesSlide DeckPress ReleaseOABI Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by OmniAb Earnings HeadlinesFY2024 EPS Estimates for OmniAb Lifted by Leerink PartnrsJanuary 11, 2025 | americanbankingnews.comKuehn Law Encourages Investors of OmniAb, Inc. to Contact Law FirmJanuary 7, 2025 | markets.businessinsider.comNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …January 19, 2025 | Weiss Ratings (Ad)Why OmniAb, Inc. (OABI) Is One of the Best Biotech Penny Stocks to Invest in Now?December 30, 2024 | msn.comWith 55% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big gunsDecember 22, 2024 | uk.finance.yahoo.comOmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics ConferenceDecember 16, 2024 | businesswire.comSee More OmniAb Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OmniAb? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OmniAb and other key companies, straight to your email. Email Address About OmniAbOmniAb (NASDAQ:OABI), a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.View OmniAb ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)Capital One Financial (1/21/2025)HDFC Bank (1/21/2025)3M (1/21/2025)Prologis (1/21/2025)Charles Schwab (1/21/2025)Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
